

Stroke Medication Table

This Medication Table pertains to the Guideline *Stroke and Transient Ischemic Attack – Management and Prevention*
www.BCGuidelines.ca

Drug	Standard Prescription	Approx Monthly Cost (Jan 2009)	PharmaCare Coverage
ASA (G)	secondary prevention, primary prevention in patients with atrial fibrillation: 80-325 mg once daily use in emergencies: refer to text	<1\$ - \$5	325 mg, 650 mg: regular benefit, LCA ≤81 mg: not a benefit
clopidogrel (Plavix®)	75 mg once daily	\$78	Limited coverage For secondary prevention in patients who have experienced treatment failure or intolerance to ASA
dipyridole 200 mg extended-release with aspirin 25 mg immediate release (Aggrenox®)	1 tablet twice daily	\$53	Not a benefit
warfarin (Coumadin®) (G)	therapy must be individualized	\$5 - \$18 for most patients	Regular benefit, LCA

Note: Please review product monographs and regularly review current listings of Health Canada advisories, warnings and recalls at:
http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/index_e.html

G: indicates that generics are available.

For more information see: <http://www.health.gov.bc.ca/pharme/>

Regular benefit drugs: do not require Special Authority. Patients may receive full or partial coverage, since some of these drugs are included in the Low Cost Alternative (LCA) program or Reference Drug Program (RDP).

LCA: When multiple medications contain the same active ingredient (usually generic products), patients receive full coverage for the drug with the lowest average PharmaCare claimed price. The remaining products are partial benefits.

Limited coverage drugs: require Special Authority. These drugs are not normally regarded as first-line therapies or there are drugs for which a more cost-effective alternative exists.

In all cases: coverage is subject to drug price limits set by PharmaCare and to the patient's PharmaCare plan rules and deductibles.